A STUDY TO ASSESS THE LONG-TERM SAFETY AND | Clinical Research Studies Listing

A STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF INTRAVENOUS ATB200 CO-ADMINISTERED WITH ORAL AT2221 IN ADULT SUBJECTS WITH LATE-ONSET POMPE DISEASE

Enrolling By Invitation

18-99 years

All

Phase 3

3 participants needed

1 Location

Brief description of study

A STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF INTRAVENOUS ATB200 CO-ADMINISTERED WITH ORAL AT2221 IN ADULT SUBJECTS WITH LATE-ONSET POMPE DISEASE

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: POMPE DISEASE,POMPE DISEASE
Age: Between 18 Years - 99 Years
Gender: All

completion of study ATB200-03 Male Female over age 18

Updated on 01 Aug 2024. Study ID: 843492

If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com